Skip to main content
Premium Trial:

Request an Annual Quote

Celliance Acquires Gene-Expression Technology from Innovata

NEW YORK, Oct. 3 (GenomeWeb News) - Celliance has acquired a gene-expression technology from Innovata for an undisclosed amount, the wholly owned Serologicals subsidiary said today.

 

The so-called ubiquitous chromatin opening element technology allows researchers to improve the yield, consistency, and stability of protein production in cultured mammalian cells. Other applications include gene therapy, transgenics, and the generation of cell lines for drug screening, according to Celliance.

 

The technology has been licensed by a number of pharmaceutical and biotechnology companies, including Medarex and Maxygen.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.